ReNetx: ReNetX Bio receives US FDA nod to begin phase 1 trial of AXER─204 to treat chronic spinal cord injury

ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system disorders, has announced that the US Food and Drug